Connor Clark & Lunn Investment Management Ltd. Has $3.93 Million Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Connor Clark & Lunn Investment Management Ltd. raised its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 4.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 819,382 shares of the biopharmaceutical company’s stock after acquiring an additional 38,449 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Vanda Pharmaceuticals were worth $3,925,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Intech Investment Management LLC acquired a new position in Vanda Pharmaceuticals in the third quarter valued at approximately $84,000. SG Americas Securities LLC raised its position in shares of Vanda Pharmaceuticals by 26.8% during the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 5,459 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Vanda Pharmaceuticals during the third quarter worth approximately $143,000. Verition Fund Management LLC raised its position in shares of Vanda Pharmaceuticals by 7.8% during the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 2,927 shares during the period. Finally, Franklin Resources Inc. raised its position in shares of Vanda Pharmaceuticals by 8.8% during the third quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 4,449 shares during the period. 88.14% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. StockNews.com assumed coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a “hold” rating on the stock. HC Wainwright upped their target price on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th.

Vanda Pharmaceuticals Trading Up 1.2 %

Shares of Vanda Pharmaceuticals stock opened at $4.98 on Monday. The stock has a fifty day simple moving average of $4.61 and a 200 day simple moving average of $4.76. Vanda Pharmaceuticals Inc. has a 12-month low of $3.71 and a 12-month high of $6.75. The company has a market capitalization of $290.41 million, a P/E ratio of -15.56 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The business had revenue of $53.19 million during the quarter, compared to the consensus estimate of $51.00 million. On average, analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Insider Buying and Selling

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock in a transaction on Friday, February 28th. The stock was purchased at an average price of $4.76 per share, for a total transaction of $47,600.00. Following the purchase, the chief executive officer now directly owns 2,361,730 shares of the company’s stock, valued at $11,241,834.80. This trade represents a 0.43 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders purchased 32,000 shares of company stock worth $151,180. 8.90% of the stock is owned by corporate insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.